MedTrace Logo

A Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette Syndrome

NCT05188274 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-01-12

No results posted yet for this study

Summary

A 12-week clinical study to evaluate the safety and efficacy of T92 in pediatric patients with Tourette Syndrome.

Conditions

  • Tourette Syndrome in Children
  • Tourette Syndrome in Adolescence

Interventions

DIETARY_SUPPLEMENT

T92

T92 granules (5g/sachet) will be taken BID for 8 weeks, the dosage will be calculated by individual's body weight.

DIETARY_SUPPLEMENT

Placebo

The placebo matched to T92 granules will be taken BID for 8 weeks.

Sponsors & Collaborators

  • Tasly Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael H Bloch, MD, PhD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2024-02-29
Completion
2024-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05188274 on ClinicalTrials.gov